Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Daniil Gataulin maintains a Buy rating on EyePoint Pharmaceuticals (NASDAQ:EYPT) and keeps the price target at $28.
June 28, 2024 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital analyst Daniil Gataulin maintains a Buy rating on EyePoint Pharmaceuticals and keeps the price target at $28.
The reaffirmation of a Buy rating and a $28 price target by Chardan Capital is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100